Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Tung Discusses the Role of Olaparib in Breast Cancer

March 30th 2018

Nadine M. Tung, MD, associate professor of medicine, Harvard Medical School, director, Cancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Center, discusses the role of olaparib (Lynparza) in the treatment of patients with breast cancer.

Dr. Muss on the Role of PARP Inhibitors in Breast Cancer

March 28th 2018

Hyman B. Muss, MD, professor of medicine, University of North Carolina-Chapel Hill School of Medicine, Breast Cancer Geriatric Oncology Program, director, geriatric oncology, UNC Lineberger Comprehensive Cancer Center, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses the addition of PARP inhibitors to the treatment landscape of breast cancer.

Dr. Brufsky on Biosimilars Being Explored in Oncology

March 28th 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses biosimilars currently being explored in cancer.

Dr. Robson on the Toxicity Profile of Olaparib in Breast Cancer

March 28th 2018

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the toxicity profile of olaparib (Lynparza) in breast cancer.

Expert Discusses Optimizing CDK 4/6 Inhibitors in Breast Cancer

March 28th 2018

Reshma Mahtani, DO, discusses the tolerability of CDK 4/6 inhibitors for the treatment of patients with metastatic breast cancer.

Dr. Mittendorf Discusses Immunotherapy Efforts in Breast Cancer

March 27th 2018

Elizabeth A. Mittendorf, MD, PhD, Robert and Karen Hale Distinguished Chair in Surgical Oncology, director, Breast Immuno-Oncology Program, Director of Research, Breast Surgical Oncology, Dana-Farber/Brigham and Women’s Cancer Center, discusses immunotherapy efforts in breast cancer.

Biosimilar Filgrastim Safety Confirmed in Analysis

March 27th 2018

EP2006, a filgrastim biosimilar, produced safety results equivalent to those observed with referent filgrastim in a combined analysis of 2 phase III breast cancer studies from the United States and Europe.

Dr. Mahtani on the Use of CDK 4/6 Inhibitors in Metastatic ER+ Breast Cancer

March 23rd 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the use of CDK 4/6 inhibitors in older patients with estrogen receptor-positive breast cancer.

Trastuzumab Biosimilar Approaches European Approval

March 23rd 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to trastuzumab.

Traina Talks TNBC Treatment Evolution

March 23rd 2018

Tiffany A. Traina, MD, discussed the potential for PARP inhibitors, as well as immunotherapy and antibody-drug conjugates, for the treatment of patients with triple-negative breast cancer.

Avoiding Unnecessary Surgery and Radiation in Low-Risk DCIS

March 21st 2018

Research suggests that many cases of DCIS have a low risk for progression and may not require surgical excision and radiation therapy.

Dr. Domchek Discusses Immunotherapy in Breast Cancer

March 21st 2018

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the development of immunotherapy in breast cancer.

Scarcity of Actionable Oncogenes Should Not Preclude Testing in Breast Cancer

March 21st 2018

Although much remains unknown about many mutations and test results rarely clarify the need for any particular response, panel testing has already demonstrated its cost value, which continues to increase every day.

Unlocking the Potential of Immunotherapy in Breast Cancer

March 21st 2018

A pair of trials that used checkpoint inhibitors as monotherapy reported lackluster overall response rates in breast cancer.

Dr. Rao on the SOFT Trial in Patients With Premenopausal Breast Cancer

March 20th 2018

Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.

Dr. Traina on PARP Inhibition in BRCA-Mutated Breast Cancer

March 19th 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the prevalence of BRCA mutations in triple-negative breast cancer (TNBC).

Optimizing HER2-Targeted Therapy

March 19th 2018

Sara Hurvitz, MD, and Sunil Verma, MD, share their expert insight on the latest groundbreaking developments in HER2-positive breast cancer.

Dr. Litton on Genetic Testing in Breast Cancer

March 19th 2018

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of genetic testing in the treatment of patients with breast cancer.

An Early Voice for Breast Conservation Therapy Reflects on a Changing Field

March 17th 2018

As a trailblazer who helped breast cancer treatment evolve from radical mastectomy to the judicious use of radiation therapy with limited tumor removal, Samuel Hellman, MD, is considered one of the world's premier radiation oncologists.

Dr. Freedman on the NCCN Guidelines for Post-Mastectomy Radiation

March 17th 2018

Laura M. Freedman, MD, assistant professor, director of Radiation Oncology, Sylvester Comprehensive Cancer Center, discusses the revised National Comprehensive Cancer Network (NCCN) guidelines for post-mastectomy radiation given in women who have pathologic T1 and T2 tumors and 1 to 3 positive lymph nodes.